Formulation and in vitro Evaluation of Tablet Dosage form of Unani Anti-diabetic Powder Containing Gymnema sylvestre R. Br, Syzygium cuminii Linn. and Zingiber officinale Rosc.

Background and Objectives: Diabetes Mellitus (DM) is one of the leading causes of end stage renal disease, adult blindness etc. The side effects and resistance of conventional medicines for DM had put forward a need to develop an effective antidiabetic formulation with the aid of traditional medicine. Modification of dosage form in traditional system of medicine for palatability and portability is the need of hour. The antidiabetic safoof(powder) formulation containing Gurmar buti(Gymnema sylvestre R.Br), Jamun (Syzygium cuminii Linn.) and Zanjabeel (Zingiber officinale Rosc.) is having inconvenience to follow the accurate dose, palatability and stability issues due to surface area of powder. To rectify this problem the Safoof is modified into tablet dosage form with documentation of standard manufacturing procedure, its physicochemical analysis and in vitro antidiabetic evaluation. Materials and Methods: For process standardization total 10 batches were generated for the optimum working process related to the powder size, quantity of binder, wetting, granulation, time for drying and compression by trial and error. Ideal batch was selected on the basis of set parameter (friability, hardness and disintegration time), its physicochemical standards including HPLC as well as α-amylase and α-glucosidase inhibition activity were established. Results: With excipients 5% Gum acacia, 5% CMC, 1% SSG, 0.5% Mg stearate and 0.5% Talc, the mean value of the hardness, friability and disintegration time of tablet were found to be 4.83 ± 0.17, 0.29 ± 0.01 and 14.24 ± 0.05 respectively. Physico-chemical data with HPLC quantification of Gymnemagenin, 6-Gingerol, 8-Gingerol, 6-Shogaol and 10-Gingerol were set in. The heavy metals and microbial contaminations are within permissible limit. Antidiabetic activity through α-amylase and α-glucosidase inhibition were 0.00 ± 0.00 at the 2500 μg/ml and 84.28 ± 0.58% at the 3000 μg/ml concentration respectively. Conclusion: Classical powder is modified effectively in tablet dosage form with in vitro evaluation of its antidiabetic activity particularly α-glucosidase inhibition of crude powder and standardization data was also set in.